Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria. The study also intends to evaluate clinical treatment success using a novel clinical endpoint for drug development in severe malaria. Severe malaria is a medical emergency and is affecting primarily young children in Africa. Injectable artesunate is the standard of care for the treatment of severe malaria and is highly efficacious. However, the spread of artemisinin-resistance in Plasmodium falciparum in Asian countries poses a threat for future treatment of patients with this life-threatening disease. To mitigate this risk, there is a need of another drug in malaria endemic countries. Cipargamin treatment results in rapid clearance of parasites including artemisinin resistant parasites.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04675931
Study type Interventional
Source Novartis
Contact Novartis Pharmaceuticals
Phone +41613241111
Email novartis.email@novartis.com
Status Recruiting
Phase Phase 2
Start date March 7, 2022
Completion date May 20, 2025

See also
  Status Clinical Trial Phase
Completed NCT01955382 - Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria Phase 2
Not yet recruiting NCT01122134 - Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment N/A
Recruiting NCT05685875 - Association of Diabetes and Metabolic Syndrome With Severe Malaria in Cameroon
Completed NCT02451904 - Severe and Cerebral Malaria Investigated Through Host Metabolomics
Completed NCT04037332 - Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
Completed NCT00341003 - Severe Malaria and Anti-malarial Drug Resistance in Cambodia N/A
Completed NCT01255215 - Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial Phase 1/Phase 2
Completed NCT05140278 - Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate Phase 2
Recruiting NCT05711485 - Platelet-Directed Whole Blood Transfusion Strategy for Malaria N/A
Completed NCT04473768 - Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children
Completed NCT04176029 - Lung Ultrasound in Children With Severe Malaria
Recruiting NCT06064591 - Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
Recruiting NCT04251351 - Effect of Paracetamol on Kidney Function in Severe Malaria Phase 3
Completed NCT00342043 - Examination of Protective Factors Against Severe Malaria N/A
Completed NCT04516317 - Very Severe Malaria Treated by Intravenous Artesunate
Completed NCT01828333 - Malaria Treatment With Injectable ArteSunate N/A